Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Oct 27, 2020HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female FoundersOct 26, 2020HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19Sep 24, 2020HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare AwardSep 17, 2020HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS® Single-Cell Platform at 2020 AACR Tumor Heterogeneity ConferenceSep 3, 2020KITE AND HIFIBIO THERAPEUTICS PARTNER TO DISCOVER NOVEL TARGETS AND ANTIBODIES AGAINST ACUTE MYELOID LEUKEMIA< 1 … 8 9 10 11 12 … 17 >
